Drug Profile
Ciltacabtagene autoleucel - Janssen Biotech/Nanjing Legend Biotech
Alternative Names: BCMA CAR-T - Janssen Biotech; BCMA CAR-T cell therapy- Janssen Biotech/Nanjing Legend Biotech; CAR-T cell therapy - Nanjing; CARVYKTI; cilta-cel; JNJ 4528; JNJ-68284528; LCAR-B38M; LCAR-B38M CAR-T cell therapy; LCARB38M/JNJ-4528Latest Information Update: 22 Mar 2024
Price :
$50
*
At a glance
- Originator Legend Biotech USA; Nanjing Legend Biotech
- Developer Janssen Biotech; Legend Biotech USA; Nanjing Legend Biotech
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Multiple myeloma
- Phase II Smoldering multiple myeloma
Most Recent Events
- 22 Mar 2024 U.S Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee (ODAC) recommends approval of Ciltacabtagene autoleucel for Multiple myeloma (Second-line therapy or greater for patients who have received at least one prior line of therapy) in USA
- 11 Mar 2024 Launched for Multiple myeloma (Second-line therapy or greater) in Austria (IV)
- 11 Mar 2024 Launched for Multiple myeloma (Second-line therapy or greater) in Germany (IV)